Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study

In patients with polycythemia vera (PV), an elevated JAK2 p.V617F allele burden is associated with indicators of more severe disease (e.g., leukocytosis, splenomegaly, and increased thrombosis risk); however, correlations between allele burden reductions and clinical benefit in patients with PV have...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Ann Hematol
Autores principales: Vannucchi, Alessandro Maria, Verstovsek, Srdan, Guglielmelli, Paola, Griesshammer, Martin, Burn, Timothy C., Naim, Ahmad, Paranagama, Dilan, Marker, Mahtab, Gadbaw, Brian, Kiladjian, Jean-Jacques
Formato: Artigo
Lenguaje:Inglês
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5486779/
https://ncbi.nlm.nih.gov/pubmed/28456851
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00277-017-2994-x
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares